Short Answer
Sermorelin vs Tesamorelin: The Short Answer
Sermorelin and tesamorelin are both analogs of growth hormone-releasing hormone (GHRH). Each binds the GHRH receptor on the pituitary gland and prompts it to release the body's own growth hormone. Neither one is growth hormone itself.
The two differ in three ways that matter: structure, regulatory status and the quality of the evidence. Tesamorelin has two phase 3 trials and one FDA-approved use. Sermorelin has an older approval that no longer exists as a marketed product, and a handful of small studies in older adults. No published trial has put one against the other.
Protocol Health prescribes compounded sermorelin and offers tesamorelin through clinician-supervised care when appropriate, so we have a commercial interest in both and say so here. That is the reason this comparison is built on drug labels, the Federal Register and published trials, including the ones that are unflattering to sermorelin.
Book a peptide consultationThe Difference
What Is the Difference Between Sermorelin and Tesamorelin?
The difference between sermorelin and tesamorelin starts with length. Natural human GHRH is a chain of 44 amino acids. Sermorelin is the first 29 of them, described in a 1999 drug review as the shortest synthetic peptide with full biological activity of GHRH. Tesamorelin keeps all 44 and adds a hexenoyl group, a six-carbon chain, to the first amino acid, according to the Egrifta SV prescribing information.
That added group is intended to stabilize the molecule. It is often described as making tesamorelin long-acting, which overstates it. The Egrifta SV label reports a half-life of 8 minutes in healthy subjects after a single subcutaneous dose. Both peptides are short-lived signals that produce a pulse of growth hormone, and both were given by injection at least once a day in their trials.
| Sermorelin | Tesamorelin | |
|---|---|---|
| What it is | The first 29 amino acids of human GHRH | All 44 amino acids of human GHRH plus a hexenoyl group |
| Brand name | Geref (discontinued in 2008) | Egrifta |
| Current FDA-approved use | None | Reducing excess abdominal fat in adults with HIV-associated lipodystrophy |
| How it is obtained today | Compounded only; an unapproved drug | As the approved brand; a compounded version is not FDA-approved |
| Largest body-composition trial cited here | 19 adults over 16 weeks, with a close analog | 806 adults across two phase 3 trials |
| Best-documented effect | Higher overnight growth hormone release | About 15% less visceral fat over 26 weeks in adults with HIV |
For a fuller account of each molecule on its own, see our guides to what sermorelin is and what tesamorelin is.
FDA Status
Are Sermorelin and Tesamorelin FDA-Approved?
Tesamorelin is FDA-approved for one use, and sermorelin is not currently approved for any. The details are where most comparisons go wrong.
Sermorelin: approved once, compounded now
Sermorelin was sold as Geref. The FDA approved it in 1990 as a diagnostic agent for testing pituitary function and in 1997 for idiopathic growth hormone deficiency in children with growth failure. The manufacturer discontinued it in 2008. In 2013 the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, 2013).
No treatment indication for adults was ever approved. Sermorelin prescribed to adults today is compounded by a pharmacy, and compounded sermorelin is an unapproved drug. It has not been reviewed by the FDA for safety, effectiveness or quality.
Tesamorelin: approved for one population
Tesamorelin is sold as Egrifta. Its label indicates it for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy, and for nothing else. Prescribing the brand for general body composition or longevity is off-label. A compounded tesamorelin is not FDA-approved.
The label also sets limits that rarely make it into marketing. It states that Egrifta is not indicated for weight loss management because it has a weight-neutral effect, and that its long-term cardiovascular safety has not been established.
The FDA maintains a list of bulk drug substances that may present significant safety risks in compounding. When we checked it on October 6, 2026, the page was dated April 22, 2026, and neither sermorelin nor tesamorelin appeared on it. Absence from that list is not an approval, and the list changes, so it is worth checking the current version.
Tesamorelin Evidence
What the Tesamorelin Trials Measured
Tesamorelin has randomized phase 3 evidence, all of it in adults with HIV who had accumulated abdominal fat on antiretroviral therapy. In the first phase 3 trial, published in the New England Journal of Medicine in 2007, 412 patients received a daily injection of tesamorelin or placebo for 26 weeks. The trial used 2 mg daily. Visceral fat measured by CT fell 15.2% on tesamorelin and rose 5.0% on placebo. IGF-1 rose 81.0%.
A pooled analysis of both phase 3 trials covered 806 patients. The treatment effect on visceral fat at 26 weeks was 15.4%, with no significant change in the fat under the skin. Patients who continued for 52 weeks kept the reduction, and glucose measures did not differ meaningfully from placebo.
Two findings temper that result. In the 52-week extension, visceral fat came back after tesamorelin was stopped, and the authors concluded that the effect does not last beyond the duration of treatment. And in the 2007 trial, more patients on tesamorelin withdrew because of an adverse event, even though overall adverse event rates were similar.
Outside HIV, the evidence is small
A 12-month trial in 60 adults with abdominal obesity and reduced growth hormone secretion found that tesamorelin reduced visceral fat compared with placebo, again without changing fat under the skin. A 20-week trial in 152 adults aged 55 to 87, some with mild cognitive impairment, reported a favorable effect on a cognitive test battery, and its authors called for longer trials. These are single studies in specific groups. They do not establish tesamorelin as a treatment for general fat loss, aging or memory, and the phase 3 trials tested the manufacturer's product, not a compounded one.
Sermorelin Evidence
What the Sermorelin Trials Measured
Sermorelin's evidence in adults is older, smaller and less consistent than tesamorelin's. Its approvals rested on diagnostic and pediatric studies. The adult body-composition trials cited here date from the 1990s and enrolled between 10 and 19 people each.
In a 1997 single-blind trial, 19 men and women aged 55 to 71 injected a close analog of sermorelin nightly for 16 weeks. Overnight growth hormone release rose in both sexes. Lean body mass increased in men only, skin thickness increased in both sexes, and there were no other changes in body composition. Sleep quality was unaffected in both sexes. The only adverse effect reported was a transient rise in blood lipids.
In a second 1997 study, 11 healthy men aged 64 to 76 injected sermorelin nightly for 6 weeks, with no placebo group. Nocturnal growth hormone release rose, but IGF-1 did not change. Two of six strength measures improved. Weight, body mass index, and DEXA measures of muscle and fat did not change. The authors concluded that a single nightly dose was less effective than multiple daily doses.
That last point echoes an earlier study in which 10 older men took sermorelin twice daily for 14 days. At the higher of two doses, growth hormone and IGF-1 rose to levels that no longer differed from those of young men. It was a two-week hormone study, not a body-composition trial.
Taken together, these studies show that sermorelin reliably raises growth hormone release in older adults. They do not show a reduction in visceral fat, and they do not show a consistent gain in muscle. Sermorelin has no trial resembling tesamorelin's phase 3 program.
Which Is Better
Is Tesamorelin Better Than Sermorelin? No Trial Has Compared Them
Whether tesamorelin is better than sermorelin cannot be answered from data, because nobody has run the comparison. A PubMed search for the two names together returned 12 records when we ran it in October 2026: review articles and anti-doping laboratory methods. None was a clinical trial comparing the two.
What can be said is narrower. Tesamorelin has stronger evidence for one outcome, visceral fat, in one population, adults with HIV-associated lipodystrophy. Sermorelin has weaker evidence for every outcome. Weaker evidence is not the same as a weaker drug. It means the trials that would settle the question were never done.
Comparing percentages across separate trials does not fix this. The tesamorelin and sermorelin studies enrolled different people, used different doses for different lengths of time, and measured different things. Forum and Reddit discussions tend to rank the two by personal experience. Those accounts are real to the people writing them, and they are not a controlled comparison.
Cost and access also differ and are worth raising at a consultation.
By Goal
Sermorelin or Tesamorelin for Fat Loss, Muscle Growth and Sleep
Choosing sermorelin or tesamorelin by goal means separating what people hope for from what trials measured.
- Visceral fat. Tesamorelin reduced visceral fat by about 15% over 26 weeks in adults with HIV-associated lipodystrophy. Patients often seek sermorelin for abdominal fat; controlled trials have not confirmed it.
- Weight loss. Neither peptide is a weight-loss drug. The Egrifta label describes tesamorelin's effect as weight neutral, and body weight was unaffected in the 16-week sermorelin-analog trial.
- Muscle growth. Patients often seek sermorelin or tesamorelin for muscle growth; controlled trials have not confirmed it for either. Lean mass rose in men only in one 19-person trial of a sermorelin analog and did not change in the 6-week sermorelin study. Tesamorelin's phase 3 trials were designed around visceral fat, not muscle.
- Sleep. Patients often seek sermorelin for sleep; controlled trials have not confirmed it. The 16-week analog trial, which assessed sleep quality by questionnaire, found it unaffected.
- Skin and aging. Skin thickness increased in one small sermorelin-analog trial. No controlled trial shows that sermorelin or tesamorelin slows aging.
Resistance training, adequate protein and sleep habits remain the levers with consistent evidence for muscle and recovery. A peptide is at most one part of a plan that a clinician builds around your labs and history.
Side Effects
Sermorelin and Tesamorelin Side Effects and Who Should Avoid Them
Sermorelin and tesamorelin share the side effects expected of anything that raises growth hormone, but tesamorelin's are far better documented. The Egrifta SV label lists the most common adverse reactions, each reported in more than 5% of patients, as joint pain, injection site redness and itching, pain in the extremities, peripheral edema and muscle pain.
The same label warns about fluid retention, glucose intolerance or diabetes, hypersensitivity reactions and elevated IGF-1, and it instructs prescribers to monitor IGF-1 and glucose. It contraindicates tesamorelin in pregnancy, in people with active malignancy, in people with a known hypersensitivity to it, and in people whose hypothalamic-pituitary axis has been disrupted by surgery, tumor, radiation or head trauma.
Sermorelin's safety record comes mostly from children. In pediatric studies the most commonly reported adverse events were transient facial flushing and pain at the injection site. Adult studies were too small and too short to detect uncommon harms, and compounded sermorelin carries no FDA-reviewed label. The cautions that apply to tesamorelin are reasonable to assume for sermorelin, since both act on the same receptor.
Neither peptide has long-term safety data in healthy adults using it for body composition or aging. If you develop swelling, persistent joint pain, numbness or tingling in the hands, or signs of an allergic reaction, contact a clinician promptly.
Together
Can You Take Sermorelin and Tesamorelin Together?
No trial has tested sermorelin and tesamorelin together, so a tesamorelin and sermorelin stack has no evidence behind it. The pharmacology does not suggest an obvious reason for one. Both peptides act on the same GHRH receptor, so combining them duplicates a single signal instead of adding a second mechanism.
The known risks, on the other hand, scale with growth hormone and IGF-1 exposure. The Egrifta SV label states that the effects of prolonged IGF-1 elevation are unknown. Whether any combination of growth hormone-related peptides is appropriate is a prescriber's decision made against labs, not something to assemble independently.
Ipamorelin
Sermorelin vs Tesamorelin vs Ipamorelin
Ipamorelin belongs to a different class from sermorelin and tesamorelin. Sermorelin and tesamorelin mimic GHRH. Ipamorelin mimics ghrelin and acts on a separate receptor to trigger growth hormone release.
Ipamorelin has never been FDA-approved for any use. The FDA's bulk-substances page lists ipamorelin acetate among the substances that may present significant safety risks, citing possible immune reactions and a published report of serious adverse events when it was given intravenously.
Our comparison of sermorelin vs ipamorelin covers that pairing in detail, and the CJC-1295 and ipamorelin guide covers the combination most often marketed alongside them.
Our Approach
How Protocol Health Approaches Sermorelin or Tesamorelin
Protocol Health is a physician-led practice in Scarsdale, New York. In-person visits take place in Scarsdale only, and telehealth is available in NY, NJ, CT, FL and CA. The Protocol Health peptide consultation starts with your history, medications and goals, and a clinician reviews them, with labs where indicated, before any prescription is considered.
Protocol Health prescribes compounded sermorelin and offers tesamorelin when a clinician judges either appropriate, and the clinic has a commercial interest in that decision. Egrifta is FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy, other use of it is off-label, and a compounded tesamorelin is not FDA-approved. Some people who ask about either peptide are better served by a different plan, and a consultation can end with that advice.
Sermorelin vs tesamorelin is a comparison between a peptide with narrow, solid evidence and a peptide with broad use and thin evidence. Tesamorelin is FDA-approved to reduce abdominal fat in adults with HIV-associated lipodystrophy and has phase 3 trials behind that one use. Sermorelin is a compounded, unapproved drug supported by small older studies that show more growth hormone release and little consistent change in body composition. No trial has compared them. This article is educational and is not a substitute for individualized medical advice; suitability, dose and monitoring are decided with a qualified clinician who knows your full picture.
FAQ
Frequently Asked Questions
Is tesamorelin the same as sermorelin?
No. Both are synthetic versions of growth hormone-releasing hormone, but sermorelin is the first 29 amino acids of the natural hormone and tesamorelin is the full 44 with an added chemical group. Tesamorelin is FDA-approved as Egrifta for one use. Sermorelin is available today only as a compounded, unapproved drug.
Is tesamorelin better than sermorelin?
No trial has compared them, so there is no data-based answer. Tesamorelin has stronger evidence for reducing visceral fat in adults with HIV-associated lipodystrophy. Sermorelin's adult studies were small and showed little consistent change in body composition. Which one, if either, suits you is a clinician's judgment.
Is tesamorelin or sermorelin better for fat loss?
Tesamorelin reduced visceral fat by about 15% over 26 weeks in phase 3 trials in adults with HIV-associated lipodystrophy, and its label says it is weight neutral and not indicated for weight loss. Sermorelin has not been shown to reduce visceral fat in a controlled trial. Neither is a general weight-loss medicine.
Which is better for muscle growth, sermorelin or tesamorelin?
Controlled trials have not confirmed muscle growth with either peptide. In one 19-person trial of a sermorelin analog, lean mass rose in men only, and a 6-week sermorelin study found no change in muscle on DEXA. Tesamorelin's main trials measured visceral fat. Resistance training and protein remain the reliable levers.
Can you take sermorelin and tesamorelin together?
No trial has tested the combination. Both act on the same GHRH receptor, so stacking them duplicates one signal, while the known risks rise with growth hormone and IGF-1 exposure. Any decision to combine growth hormone-related peptides belongs to a prescriber who is monitoring your labs.
How do sermorelin and tesamorelin compare with ipamorelin?
Sermorelin and tesamorelin mimic growth hormone-releasing hormone, while ipamorelin mimics ghrelin and works through a different receptor. Ipamorelin has never been FDA-approved for any use and appears on the FDA's list of bulk substances that may present significant safety risks. Tesamorelin has the most trial evidence of the three.
Explore
Related at Protocol Health
Book a peptide consultationThis article is educational and is not medical advice. It does not diagnose, prevent, treat or cure any condition. Talk with a licensed clinician about your own situation.